China moves to restrict exports of select biotech technology

China's commerce ministry is pursuing tighter limits on domestic companies exporting select biopharma technology, covering cell and gene therapy, siRNA and pathogen-related platforms, while ordinary drug licensing deals would continue.

Why it matters: Export controls on biotech platforms would add a new constraint on China-West dealmaking in life sciences, even as standard drug licensing, the main channel for such deals, is left open.

Data as of Endpoints News reporting published 15:28 UTC on 2026-10-16. The article itself is paywalled; this item is based on the publisher's own summary of its reporting, opened in the browser, and is graded C for that limitation. No enactment date was reported.

China’s Ministry of Commerce is moving to restrict exports of select biopharma technology by domestic companies, according to Endpoints News, with the proposed limits covering cell and gene therapy, siRNA and pathogen-related technology. Ordinary drug licensing deals would be preserved under the approach described, leaving the main channel for China-West life sciences deals open.

Shares in WuXi AppTec fell 2.19 percent on the report. The measure was described as a proposal being pursued, not an enacted ban, and no timeline was reported.

China moves to restrict exports of select biotech technology

Sources